IP Library Granted Patent US 11,839,648
Granted Patent B2
US 11,839,648 · App. 16/979,970 · Granted Dec 12, 2023

Autologous cancer vaccines

Inventors: Patrick Frayssinet (Saint Lys, FR); Nicole Rouquet (Toulouse, FR)
Assignee: HASTIM
A61K39/0011A61K9/0019A61K39/39516C01B25/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,839,648
App. No.
16/979,970
Granted
Dec 12, 2023
Kind
B2
Abstract

The invention relates to an autologous cancer vaccine and also to the method for producing same comprising the following steps: a) extracting the proteins contained in a serum or plasma sample obtained from a patient suffering from cancer; and b) bringing the proteins extracted in step a) into contact with particles of hydroxyapatite and/or tricalcium phosphate.

Claims (11)

1. A method for treating a patient suffering from a cancer, said method comprising the following steps:

a) extracting proteins contained in a serum or plasma sample obtained from a patient suffering from cancer;

b) bringing the proteins extracted in step a) into contact with particles of hydroxyapatite and/or of tricalcium phosphate;

c) suspending, in an injection liquid, the particles of hydroxyapatite and/or of tricalcium phosphate brought into contact with the proteins in step b);

d) injecting the mixture obtained in step c) into the patient from whom the serum or plasma sample used in step a) was obtained.

2. The method as claimed in claim 1 , wherein the patient is a human.

3. The method as claimed in claim 1 , wherein the patient is a dog, a horse or a cat.

4. The method as claimed in claim 1 , wherein the cancer is chosen from melanomas, carcinomas, adenocarcinomas, sarcomas, central nervous system tumors, leukemias, lymphomas and cancers of infectious origin.

5. The method as claimed in claim 1 , wherein the cancer is chosen from the group consisting of osteosarcomas, B or T lymphomas, mammary tumors, melanomas, hemangio-sarcomas, mastocytomas, fibrosarcomas, brain or central nervous system tumors, schwannomas, mesotheliomas, seminomas, teratomas and blastomas.

6. The method as claimed in claim 1 , wherein the cancer is a glioblastoma, a sarcoma, a melanoma, a carcinoma or an adenocarcinoma.

7. The method as claimed in claim 1 , wherein the cancer is a cancer exhibiting metastases.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE ADDRESS OF THE ASSIGNEE PREVIOUSLY RECORDED ON REEL 058786 FRAME 0553. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded May 5, 2022
From: URODELIA
To: HASTIM
Reel/Frame 059856/0870 →
CHANGE OF NAME Recorded Jan 27, 2022
From: URODELIA
To: HASTIM
Reel/Frame 058786/0553 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2021
From: FRAYSSINET, PATRICK; ROUQUET, NICOLE
To: URODELIA
Reel/Frame 054823/0147 →
Priority Claims (1)
FR 1852197 · Mar 14, 2018 · national
Continuity (1)
Related Publication 20210008187A1 · Jan 14, 2021